Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

2.21
-0.0700-3.07%
Post-market: 2.210.00000.00%19:30 EDT
Volume:798.26K
Turnover:1.77M
Market Cap:238.68M
PE:-3.89
High:2.30
Open:2.27
Low:2.13
Close:2.28
52wk High:6.30
52wk Low:1.58
Shares:108.00M
Float Shares:95.39M
Volume Ratio:0.92
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5680
EPS(LYR):-0.4448
ROE:-757.48%
ROA:-37.70%
PB:19.15
PE(LYR):-4.97

Loading ...

Company Profile

Company Name:
NervGen Pharma Corp.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
10
Office Location:
112-970 Burrard Street,Unit 1290,Vancouver,British Columbia,Canada
Zip Code:
V6Z 2R4
Fax:
- -
Introduction:
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.